RECIST Oncology Guidelines
After it's introduction in 2000, RECIST (Response Evaluation Criteria in Solid Tumors) has evolved to meet industry needs as novel therapies come into development. This piece walks through how RECIST is used in oncology trials including when and why to implement iRECIST and itRECIST.
downloadExplore Our Key Related Services
Please fill out this form to access your resource.